Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

Elliott, William J, Meyer, Peter M · 2007 · The Lancet

Abstract

Background The effect of different classes of antihypertensive drugs on incident diabetes mellitus is controversial because traditional meta-analyses are hindered by heterogeneity across trials and the absence of trials comparing angiotensin-converting-enzyme (ACE) inhibitors with angiotensin-receptor blockers (ARB). We therefore undertook a network meta-analysis, which accounts for both direct and indirect comparisons to assess the effects of antihypertensive agents on incident diabetes.Methods We undertook a systematic review up to Sept 15, 2006, and identified 48 randomised groups of 22 clinical trials with 143,153 participants who did not have diabetes at randomisation and so were eligible for inclusion in our analysis. 17 trials enrolled patients with hypertension, three enrolled high-risk patients, and one enrolled those with heart failure. The main outcome was the proportion of patients who developed diabetes.Findings Initial drug therapy used in the trials (and the number of patients with diabetes of the total number at risk) included: an ARB (1189 of 14,185, or 8.38%), ACE inhibitor (1618 of 22,941, or 7.05%), calcium-channel blocker (CCB, 2791 of 38,607, or 7.23%), placebo (1686 of 24,767, or 6.81%), beta blocker (2705 of 35,745, or 7.57%), or diuretic (998 of 18,699, or 5.34%). With an initial diuretic as the standard of comparison (eight groups), the degree of incoherence (a measure of how closely the entire network fits together) was small (omega=0.000017, eight degrees of freedom). The odds ratios were: ARB (five groups) 0.57 (95% CI 0.46-0.72, p<0.0001); ACE inhibitor (eight groups) 0.67 (0.56-0.80, p<0.0001); CCB (nine groups): 0.75 (0.62-0.90, p=0.002); placebo (nine groups) 0.77 (0.63-0.94, p = 0.009); beta blocker (nine groups) 0.90 (0.75-1.09, p=0.30). These estimates changed little in many sensitivity analyses.Interpretation The association of antihypertensive drugs with incident diabetes is therefore lowest for ARB and ACE inhibitors followed by CCB and placebo, beta blockers and diuretics in rank order.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(07)60108-1

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 64 references

Research works printed but not linked: 2

  1. 2004, Position statement: diagnosis and classification of diabetes mellitus, Diabetes Care, 27, S5
  2. 2006, Hypertension: management of hypertension in adults in primary care, a partial update of NICE clinical guideline 18

Cited by

See all 1,016

Metadata

Authors
Elliott, W. J., & Meyer, P. M.
Affiliations
Rush University Medical Center (US)
Corresponding author
Elliott, William J
Venue
The Lancet
Publisher
Elsevier BV
Published
2007-01
Volume
369
Issue
9557
Pages
201-207
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2159854507
Cited by
1,016
References
64
Citations by year
2026: 11 · 2025: 18 · 2024: 27 · 2023: 21 · 2022: 29 · 2021: 23 · 2020: 36 · 2019: 45 · 2018: 33 · 2017: 34 · 2016: 52 · 2015: 61 · 2014: 73 · 2013: 69 · 2012: 71
FWCI
18.29
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5k25hl068139-05)
  • National Institute of Standards and Technology
  • National Heart, Lung, and Blood Institute (K25 HL68139-01A1)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Keywords
new-onset diabetes, antihypertensive drugs, hypertension, ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, beta-blockers, diuretics, high-risk patients, heart failure, placebo comparison, risk of bias assessment
MeSH terms
Antihypertensive Agents, Diabetes Mellitus, Humans, Hypertension, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(07)60108-1
The paper
Elliott, W. J., & Meyer, P. M. (2007). Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. The Lancet. https://doi.org/10.1016/s0140-6736(07)60108-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.